Effect of setting, monitoring intensity and patient experience on anticoagulation control: A systematic review and meta-analysis of the literature

Current Medical Research and Opinion

Volumn 24, Issue 5, 2008, Pages 1459-1472

  Dolan, G ^a   Smith, L A ^b   Collins, S ^c   Plumb, J M ^d  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

^b OXFORD BROOKES UNIVERSITY   (United Kingdom)

^c Decision Resources Group   (United Kingdom)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Anticoagulation; Atrial fibrillation; INR; Systematic review

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; PHENPROCOUMON; WARFARIN;

ANTICOAGULATION; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSENSUAL VALIDITY; EXPERIENCE; HEALTH CARE; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MEDICAL LITERATURE; META ANALYSIS; PATIENT MONITORING; PRACTICE GUIDELINE; RANDOM SAMPLE; REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; META-ANALYSIS AS TOPIC; MONITORING, PHYSIOLOGIC; PATIENT COMPLIANCE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STROKE; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 44349168228     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079908X297349     Document Type: Review

References (46)

1. Reynolds MW, Fahrbach K, Hauch O, et al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest 2004;126:1938-45
2. Samsa GP, Matchar DB. Relationship between test frequency and outcomes of anticoagulation: a literature review and commentary with implications for the design of randomized trials of patient self-management. J Thromb Thrombolysis 2000;9:283-92
3. Cannegieter SC, Rosendaal FR, Wintzen AR, et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995;333:11-17
4. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in Collaboration With the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 2001;38:1231-66
5. Fitzmaurice DA, Murray ET, McCahon D, et al. Self management of oral anticoagulation: randomised trial. BMJ 2005;331:1057
6. Holm T, Lassen JF, Husted SE, et al. A randomized controlled trial of shared care versus routine care for patients receiving oral anticoagulant therapy. J Intern Med 2002;252:322-31
7. Albers GW, Diener HC, Frison L, et al.; SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005;293:690-8
8. Pérez Gómez F, Alegria E, Berjón J, et al.; NASPEAF Investigator. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. J Am Coll Cardiol 2004;44:1557-66
9. Olsson SB. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003;362:1691-8
10. Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006;367:1903-12
11. van Walraven C, Jennings A, Oake N, et al. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest 2006;129:1155-66
12. Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 2003;107:1692-711
13. Abdelhafiz AH, Wheeldon NM. Results of an open-label, prospective study of anticoagulant therapy for atrial fibrillation in an outpatient anticoagulation clinic. Clin Ther 2004;26:1470-8
14. Connolly SJ, Laupacis A, Gent M, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991;18:349-55
15. Gurwitz JH, Monette J, Rochon PA, et al. Atrial fibrillation and stroke prevention with warfarin in the long-term care setting. Arch Intern Med 1997;157:978-84
16. Lackie CL, Garbarino KA, Pruetz JA. Warfarin therapy for atrial fibrillation in the elderly. Ann Pharmacother 2002;36:200-4
17. Matchar DB. Do anticoagulation management services improve care? Implications of the Managing Anticoagulation Services Trial. Cardiac Electrophysiol Rev 2003;7:379-81
18. McCormick D, Gurwitz JH, Goldberg RJ, et al. Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting. Arch Intern Med 2001;161:2458-63
19. Menzin J, Boulanger L, Hauch O, et al. Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: a multi-site managed-care study. Ann Pharmacother 2005;39:446-51
20. van Geest-Daalderop JH, Hutten BA, Sturk A, Levi MM. Age and first INR after initiation of oral anticoagulant therapy with acenocoumarol predict the maintenance dosage. J Thromb Thrombolysis 2003;15:197-203
21. Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003;290:2685-92
22. Samsa GP, Matchar DB, Goldstein LB, et al. Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. Arch Intern Med 2000;160:967-73
23. Kalra L, Yu G, Perez I, et al. Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness. BMJ 2000;320:1236-9
24. Jones M, McEwan P, Morgan CL, et al. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with nonvalvar atrial fibrillation: a record linkage study in a large British population. Heart 2005;91:472-7
25. Evans A, Perez I, Yu G, Kalra L. Secondary stroke prevention in atrial fibrillation: lessons from clinical practice. Stroke 2000;31:2106-11
26. Evans A, Perez I, Yu G, Kalra L. Should stroke subtype influence anticoagulation decisions to prevent recurrence in stroke patients with atrial fibrillation? Stroke 2001;32:2828-32
27. Gullov AL, Koefoed BG, Petersen P, et al. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med 1998;158:1513-21
28. Khan TI, Kamali F, Kesteven P, et al. The value of education and self-monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation. Br J Haematol 2004;126:557-64
29. Pengo V, Zasso A, Barbero F, et al. Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation. Am J Cardiol 1998;82:433-7
30. Lackner TE, Battis GN. Use of warfarin for nonvalvular atrial fibrillation in nursing home patients. Arch Fam Med 1995;4:1017-26
31. British Committee for Standards in Haematology, Haemostasis and Thrombosis Task Force. Guidelines on oral anticoagulation: third edition. Br J Haematol 1998;101:374-87
32. Milligan PE, Banet GA, Waterman AD, et al. Substitution of generic warfarin for Coumadin in an HMO setting. Ann Pharmacother 2002;36:764-8
33. Holm T, Deutch S, Lassen JF, et al. Prospective evaluation of the quality of oral anticoagulation management in an outpatient clinic and in general practices. Thromb Res 2002;105:103-8
34. Chan TY, Miu KY. Hemorrhagic complications of anticoagulant therapy in Chinese patients. J Chinese Med Assoc 2004;67:55-62
35. Beyth R J QL, Landefeld C S. A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. Ann Intern Med 2000;133:687-95
36. Waterman AD, Milligan PE, Bayer L, et al. Effect of warfarin nonadherence on control of the International Normalized Ratio. Am J Health Syst Pharm 2004;61:1258-64
37. van Deelen BA, van den Bemt PM, Egberts TC, et al. Cognitive impairment as determinant for sub-optimal control of oral anticoagulation treatment in elderly patients with atrial fibrillation. Drugs Aging 2005;22:353-60
38. Bona RD, Sivjee KY, Hickey AD, et al. The efficacy and safety of oral anticoagulation in patients with cancer. Thromb Haemost 1995;74:1055-8
39. Casais P, Luceros AS, Meschengieser S, et al. Bleeding risk factors in chronic oral anticoagulation with acenocoumarol. Am J Hematol 2000;63:192-6
40. Chiquette E, Amato G, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and heakh care costs. Arch Intern Med 1998;158:1641-7
41. You JH, Chan FW, Wong RS, Cheng G. Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation? Br J Clin Pharmacol 2005;59:582-7
42. Pengo V, Barbero F, Biasiolo A, et al. Prevention of thromboembolism in patients with mitral stenosis and associated atrial fibrillation: effectiveness of low intensity (INR target 2) oral anticoagulant treatment. Thromb Haemost 2003;89:760-4
43. Gadisseur APA, Van dMFJM, Adriaansen HJ, et al. Therapeutic quality control of oral anticoagulant therapy comparing the short-acting acenocoumarol and the long-acting phenprocoumon. Br J Haematol 2002;117:940-6
44. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A mediod to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993;69:236-9
45. Egger M, Davey Smith G, Schneider M. Systematic reviews of observational studies. In: Egger M, Davey Smith G, Altman DG, eds. Systematic Reviews in Healthcare. London, UK: BMJ Publishing Group, 2001
46. Beyth RJ, Quinn L, Landefeld CS. A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized, controlled trial. Ann Intern Med 2000;133:687-95